



Pharmaceutical Management Branch/Cancer Therapy Evaluation Program/Division of Cancer Treatment and Diagnosis/National Cancer Institute
6130 Executive Blvd * Suite 7149 * Rockville, Maryland 20852
Phone: (301) 496-5725 * Order fax: (301) 480-4612 * Other fax: (301) 402-0429 * E-mail: pmbafterhours@mail.nih.gov

FAQ: I have drug leftover and the study closed. What do I do?

OH NO! The study closed and you still have OODLES of agent! What's Pharmaceutical Management Branch (PMB) policy ?

"DCTD supplied investigational agents may be transferred within an institution (intra-institutional transfer) from a completed DCTD sponsored protocol to another DCTD approved protocol that utilizes the same agent and formulation." If your transfer doesn't fit neatly into these parameters, please contact PMB to request an exception to policy. Some tips to consider before requesting a transfer:

Special Exception (or Compassionate Use) protocols must be completed before agent can be transferred. To close out a Special Exception protocol, the investigator must submit a Report of Independent Investigator to the Special Exceptions Coordinator. Please contact the Special Exceptions Coordinator before requesting a TRC or Special Exception transfer.

Only non-dispensed agents in whole containers (vials, bottles, etc.) can be transferred! Approved transfers must be documented on the Drug Accountability Record Form (DARF).

Transfer Investigational Agent Forms are available on our web site, <http://ctep.cancer.gov>, and completed forms may be faxed to (301) 402-0429.

For additional information, contact PMB by phone at (301) 496-5725 or via e-mail at pmbafterhours@mail.nih.gov .

September 11, 2008

*Prepared and distributed by the Pharmaceutical Management Branch, CTEP, NCI.
Please do not re-distribute or post without permission.
Information in this FAQ is subject to change without notice; check periodically for updates.
Please contact PMB at (301) 496-5725 if you have questions.*